12943_2021_1418_MOESM3_ESM.png (1.23 MB)
Additional file 3 of MG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancer
figure
posted on 2021-09-15, 03:40 authored by Haichang Li, Pei-Hui Lin, Pranav Gupta, Xiangguang Li, Serena Li Zhao, Xinyu Zhou, Zhongguang Li, Shengcai Wei, Li Xu, Renzhi Han, Jing Lu, Tao Tan, Dong-Hua Yang, Zhe-Sheng Chen, Timothy M. Pawlik, Robert E. Merritt, Jianjie MaAdditional file 3: Supplementary Figure S3. rhMG53 treatment suppresses SG formation and enhances G3BP2 nuclear translocation in multiple NSCLC cells. SGs were induced by ATO treatment. (A) A549 cells were treated with control (top panels), rhMG53 (10 μg/mL) (2nd panels), ATO (0.5 mM) (3rd panels), or ATO (0.5 mM) plus rhMG53 rhMG53 (10 μg/mL) (lower panels) for 40 min, and the cells were analyzed by IHC staining with anti-G3BP1 and anti-G3BP2. G3BP1 was used as a SG marker. The nucleus was stained with DAPI (blue). Arrows indicate G3BP2 nuclear localization. (B) H460 cells were treated with control (top panels), rhMG53 (10 μg/mL) (2nd panels), ATO (0.5 mM) (3rd panels), or ATO (0.5 mM) plus rhMG53 rhMG53 (10 μg/mL) (lower panels) for 40 min, and the cells were analyzed by IHC staining with anti-PABP-1 and anti-G3BP2. PABP-1 was used as SG marker. The nucleus was stained with DAPI (blue). Arrows indicate G3BP2 nuclear localization.
